1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

European Medicines Agency Says mRNA COVID-19 Vaccines Safe In Pregnancy

01/18/2022 | 10:01am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 2.25% 158.15 Delayed Quote.-40.00%
MODERNA, INC. 3.78% 135.8 Delayed Quote.-48.48%
ON SEMICONDUCTOR CORPORATION 5.49% 59.33 Delayed Quote.-17.20%
PFIZER, INC. 0.52% 53.99 Delayed Quote.-9.04%
All news about BIONTECH SE
10:41aZOOM VIDEO COMMUNICATIONS, INC. : An attempt to reconnect
05/24Goldman Sachs Adjusts BioNTech's Price Target to $206 from $255, Keeps Neutral Rating
MT
05/23Wall Street rebounds with assist from banks, big tech
RE
05/23GLOBAL MARKETS LIVE : Tesla, Kohl's, Apple, JPMorgan, Bank of America...
05/23WALL STREET STOCK EXCHANGE : Biden comments reassure investors
05/23Pfizer says 3 shots of COVID-19 vaccine for children under 5 about 80% effective
AQ
05/23BIONTECH : Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Effi..
PU
05/23What you need to know about the coronavirus right now
RE
05/23Pfizer, BioNTech Say Third Dose of COVID-19 Vaccine About 80% Effective in Children Age..
MT
05/23Pfizer, BioNTech Publish Data Supporting COVID-19 Vaccine Efficacy In Children Aged Six..
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 941 M 18 089 M 18 089 M
Net income 2022 9 121 M 9 740 M 9 740 M
Net cash 2022 15 700 M 16 764 M 16 764 M
P/E ratio 2022 4,15x
Yield 2022 -
Capitalization 35 201 M 37 588 M 37 588 M
EV / Sales 2022 1,15x
EV / Sales 2023 0,93x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 144,85 €
Average target price 224,49 €
Spread / Average Target 55,0%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-40.00%37 588
GILEAD SCIENCES, INC.-10.47%81 543
REGENERON PHARMACEUTICALS, INC.9.40%74 440
VERTEX PHARMACEUTICALS23.33%69 269
WUXI APPTEC CO., LTD.-25.70%39 423
GENMAB A/S-19.73%19 850